Titrating the Effects of Mitochondrial Complex I Impairment in the Cell Physiology*

Antoni BarrientosDagger § and Carlos T. MoraesDagger parallel

From the Departments of Dagger  Neurology and  Cell Biology and Anatomy, University of Miami, School of Medicine, Miami, Florida 33136

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The mitochondrial oxidative phosphorylation system consists of five multimeric enzymes (complexes I-V). NADH dehydrogenase or complex I (CI) is affected in most of the mitochondrial diseases and in some neurodegenerative disorders. We have studied the physiological consequences of a partial CI inhibition at the cellular level. We used a genetic model (40% CI-inhibited human-ape xenomitochondrial cybrids) and a drug-induced model (0-100% CI-inhibited cells using different concentrations of rotenone). We observed a quantitative correlation between the level of CI impairment and cell respiration, cell growth, free radical production, lipid peroxidation, mitochondrial membrane potential, and apoptosis. We showed that cell death was quantitatively associated with free radical production rather than with a decrease in respiratory chain function. The results obtained with human xenomitochondrial cybrid cells were compatible with those observed in rotenone-induced 40% CI-inhibited cells. At high concentrations (5-6-fold higher than the concentration necessary for 100% CI inhibition), rotenone showed a second toxic effect at the level of microtubule assembly, which also led to apoptosis. The correlation found among all the parameters studied helped clarify the physiological consequences of partial CI inhibitions at the cellular level.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Electron transport and oxidative phosphorylation are mediated by five multimeric complexes (complexes I-V) that are embedded in the mitochondrial inner membrane. Mammalian complex I (CI)1 or NADH:ubiquinone oxidoreductase has at least 40 subunits (1), seven of which are coded by the mitochondrial DNA (mtDNA; Ref. 2), and catalyzes electron transport from NADH to ubiquinone, which is coupled to vectorial proton movements.

A CI deficiency is characteristic of mitochondrial diseases, as an isolated defect or, in most of the cases, as a part of multiple respiratory chain deficiencies. Isolated CI deficiency has been associated with a wide spectrum of symptomatic phenotypes, varying from fatal infantile lactic acidosis to some cases of Leigh's disease, adult onset exercise intolerance, and some neurodegenerative diseases as Leber's hereditary optic neuropathy (LHON), focal dystonia, and Parkinson's disease (3-6). The study of transmitochondrial cell lines harboring mtDNA from LHON patients helped explain the role of some mtDNA-coded CI subunits. Cybrids carrying the mtDNA G11778A mutation in the ND4 gene associated with LHON showed a decrease in cell respiration, but no enzymatic deficiency was detected by spectrophotometry (7). Jun et al. (8) found that the mtDNA G14459A transition in the ND6 gene associated with LHON caused a 60% CI deficiency but a mild respiratory deficiency on polarographic analysis. The function of the ND4 and ND5 subunits was studied by the characterization of rotenone-resistant mutants of a human cell line that in addition to nuclear mutations were also defective in these mtDNA-encoded CI subunits (9, 10). In addition, cybrid lines created using mtDNA from Parkinson's disease patients showed a CI deficiency and increased free radical production (11). We recently created human xenomitochondrial cybrids (HXC) (12, 13) harboring a 40% CI deficiency. The CI impairment was caused by a limited number of amino acid differences in mtDNA-coded subunits (between human and the three apes used in the creation of HXC). All these genetic models of CI deficiency have helped us assess the physiological effects of a particular level of complex I inhibition.

Some specific complex I inhibitors have been classically used to model CI deficiencies. Rotenone is an inhibitor of the NADH dehydrogenase, which shuts off the supply of electrons to the quinol (QH2)-cytochrome c oxidoreductase (14). 1-Methyl-4-phenylpyridinium, the bioactivated product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, binds to the rotenone-binding site, thereby limiting CI activity (15). Inhibition of CI by rotenone or 1-methyl-4-phenylpyridinium not only leads to a decline in mitochondrial ATP production but also enhances the generation of free radical by the mitochondrial respiratory chain and initiates lipid peroxidation reaction in isolated bovine heart mitochondria or submitochondrial particles (16-19). Because 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine causes Parkinson's disease in humans (20) and rats (21), these data suggested a role for CI deficiency and increased oxidative stress in Parkinson's disease substantia nigra and in the dopaminergic cell death in this disorder (22).

The underlying physiological consequences of a partial complex I inhibition at the cellular level remain mostly unknown. Here we report the effect of different levels of CI impairment on the cell physiology. We used a genetic model (40% CI inhibited HXC lines; Ref. 13), and a drug-induced model (partial CI inhibition in the human osteosarcoma-derived cell line 143B) with rotenone to quantitatively correlate CI inhibition and its effect on cell respiration, cell growth, free radical production, lipid peroxidation, mitochondrial membrane potential, and apoptosis.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Lines and Culture Conditions-- Human xenomitochondrial cybrids (HXC) (human-chimpanzee clone HC1, human-gorilla HG13, and human-pigmy chimpanzee clone HP4) were produced and reported previously (12). The human osteosarcoma-derived cell line 143B(TK-) and its mtDNA-less derivative, 143B/206 rho °, were cultured as described (23). Culture conditions were modified as described below under "Growth Curves." SUB21 cell line (transmitochondrial cybrid clone containing wild type mtDNA) was previously characterized (24) and used in some experiments as a human control cell line.

Genetic and Experimentally Drug-induced Models of Complex I Inhibition-- We modeled a partial CI inhibition by treating the osteosarcoma cell line 143B with different concentrations of the CI inhibitor rotenone. To define the model and to assess how the CI (NADH decylubiquinone reductase) inhibition affects the KCN-sensitive endogenous cell respiration, 143B cells were treated for 24 h with 0-1 µM rotenone. CI was measured spectrophotometrically in isolated mitochondria, and cell respiration was measured polarographically in whole cells as described previously (13). In all the experiments, the culture medium was changed 2 h before harvesting the cells. To validate the results obtained, a genetic model of CI deficiency was used. The model consisted in HXC lines harboring mtDNA from common chimpanzee (Pan troglodytes), pigmy chimpanzee (Pan paniscus), and gorilla (Gorilla gorilla; Ref. 12). HXC cells showed an approximately 20% decrease in the cell respiration and a 40% decrease in the CI activity (13).

Immunoblotting-- To determine whether the CI inhibition induced adaptive variations on the expression of the complex I and II subunits, immunoblotting was performed as described previously. 40 µg of mitochondrial proteins from 143B cells treated with rotenone during 24 h were used, as well as human succinate dehydrogenase flavoprotein subunit (SDH (Fp)) monoclonal and human ND1 polyclonal antibodies. After scanning the autoradiograms, band signals were quantified using NIH Image 1.62b7 software. The ratio between the different bands (ND1/SDH ratio) was considered as the division of the arbitrary densitometric values of the signals using each antibody. These ratios were used to compare untreated and rotenone-treated 143B cells.

Growth Curves-- Growth measurements were made by platting 5 × 104 cells on 100-cm2 dishes in 10 ml of the appropriate medium. Cells were grown in Dulbecco's modified Eagle's medium lacking glucose supplemented with 5 mM glucose or Dulbecco's modified Eagle's medium lacking glucose supplemented with 5 mM galactose, both supplemented with 1 mM pyruvate and 10% dialyzed fetal calf serum. Cells were incubated at 37 °C, and cell counts were performed at daily intervals. For 143B and 143B/206 rho ° cells, medium was supplemented with different concentrations (0-1 µM) of rotenone. HXC lines (13) were grown in media with glucose or galactose without rotenone supplementation.

Oxidative Stress Analyses-- For each assay, three independent samples from each cell type (human control lines SUB21 and 143B and the HXC lines HP4, HG13, and HC1), either intact cells (independently collected) or isolated mitochondria (independently isolated), were analyzed, and at least three measurements of each sample were obtained. To reproduce different degrees of CI inhibition, various concentrations of rotenone (0-600 nM) were added to 143B cells at approximately 80% confluence. After 4, 24, 48, and 72 h the oxidative stress determinations were conducted. Experiments were performed in triplicate.

Free Radical Production-- To monitor oxidative activity, the cell-permeant probe 2'-7' dichlorofluorescein diacetate (H2DCFDA) was used. H2DCFDA passively diffuse into cells where intracellular esterases cleave the acetates, and the oxidation of H2DCF by hydrogen peroxide produces a fluorescent response (25). Cells were collected by trypsinization. 50 µg of cellular protein were resuspended in 500 µl of phosphate-buffered saline (PBS) medium and labeled with H2DCFDA (2 µg/ml) (Molecular Probes, Eugene, OR) for 10-60 min in the dark at 37 °C. Fluorometric analyses at 507 nm excitation and 530 nm emission were performed using a MPF-66 fluorescence spectrophotometer (Perkin-Elmer Corp.). For all the measurements, the basal fluorescence (time 0, t0) was subtracted. The increase in the fluorescence was used to measure the chemical process of hydrogen peroxide production.

Lipid Peroxidation Assays-- Peroxidation of cellular lipids was measured using 50 µg of cellular protein resuspended in 500 µl of PBS and labeled with cis-parinaric acid (5 mM) (Molecular Probes, Eugene, OR) (26) for 10-60 min in the dark at 37 °C. Cells were washed by pelleting to remove excess probe, and fluorescence at 318 nm excitation and 410 nm emission was detected as described (27). Loss of parinaric acid fluorescence was used to measure the chemical process of lipid peroxidation. To measure peroxidation of mitochondrial membranes lipids, 50 µg of fresh mitochondrial protein were resuspended in 500 µl of medium A. The experimental conditions were the same as described above.

Mitochondrial Membrane Potential (Delta psi m)-- Delta psi m was estimated using 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazole carbocyanide iodide (JC-1). JC-1 is a fluorescent compound (excitation maximum, 490 nm) that exists as a monomer at low concentrations. At higher concentrations, JC-1 forms aggregates. Fluorescence of the monomer is green (emission, 527 nm), whereas that of the J-aggregate is red (emission, 590 nm). Mitochondria with intact membrane potential (higher than 100 mV) concentrate JC-1 into aggregates that fluoresce red, whereas de-energized mitochondria cannot concentrate JC-1 and fluoresce green (28). Changes in plasma membrane potential do not affect the JC-1 status. JC-1 was chosen because has been described as a reliable probe for analyzing Delta psi m changes in intact cells, whereas other different probes capable of binding mitochondria show a lower sensitivity (rhodamine 123) or a noncoherent behavior due to a high sensitivity to changes in plasma membrane potential (3-3'-dihexilocarbocyanide iodide) (29). Cells were grown in 25-cm2 dishes until 90% confluence and incubated for 45 min with 6.5 µM JC-1. Cells were collected by trypsinization, washed in PBS, and resuspended in 500 µl of PBS, and the samples were measured on a MPF-66 fluorescence spectrophotometer (Perkin-Elmer Corp.). The ratio of the reading at 590 nm to the reading at 527 nm (590/527 ratio) was considered as a relative Delta psi m value.

Cell Death Studies-- The apoptotic rotenone-induced cell death was assessed using a cell death detection enzyme-linked immunosorbent assay kit (Roche Molecular Biochemicals). Approximately 104 cells were used for the photometric enzyme immunoassay of cytoplasmic histone-associated DNA fragments after rotenone-induced cell death. 143B and 143B/206 rho ° were treated with different concentrations of rotenone and harvested at 24-72 h. To study the role of the mitochondrial permeability transition (MPT) pore in the rotenone-induced cell death, cells were pretreated for 30 min with 5 µM of the MPT inhibitor cyclosporin A (CyA) and incubated for 48 h, changing the medium every 8.5 h. As CyA is only able to prevent MPT in short term experiments, the assay was repeated with 15- and 30-h incubation periods and using 5 µM CyA and 50 µM of the phospholipase A2 inhibitor aristolochic acid (ArA) (Sigma), which enhances and prolongs the effect of CyA (30, 31). The culture medium was changed after 15 h when necessary, and the cells were processed after 30 h.

Immunocytochemical Staining-- 143B and 143B/206 rho o cells were seeded on glass coverslips and treated with different concentrations of rotenone for 24 h. Cells were fixed with 4% paraformaldehyde in PBS, permeabilized with 0.1% saponin, and incubated for 4 h with monoclonal antibody anti-alpha -tubulin (Sigma). A Texas Red-conjugated AfiniPure donkey anti-mouse IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) was used as secondary antibody. Coverslips were incubated for 30 min with 10 µg/ml bis-benzimide Hoechst 3342 (Sigma) to reveal the nuclei and mounted onto glass slides with ProLongTM Antifade kit (Molecular Probes). Fluorescence was inspected with a Wild Leitz photomicroscope (Fluovert. Heerbrugg, Switzerland).

Statistical Analysis-- The data were analyzed using the SPSS software. Results are expressed as the means ± S.D. Comparisons between cell line groups were carried out using a Levane's test (for equality of variances) and the Student's t test (for equality of means) for independent data. When a potential relationship between variables was of interest, a linear regression analysis was performed. Values with p < 0.050 were considered statistically significant.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Defining the Complex I-inhibited Models

Modeling Complex I Partial Impairment by Incubating 143B Cells with Rotenone-- The rotenone-induced model was created by titrating the effect of different concentrations of the drug on the CI activity, measured as NADH decylubiquinone reductase. Exposure of 143B cells to increasing concentrations of rotenone produced a progressive inhibition of CI activity in isolated mitochondria (Fig. 1). A 100% inhibition was achieved with 100 nM rotenone. The endogenous cell respiration was also inhibited in a dose-dependent manner but showed different inhibition kinetics (Fig. 1). CI inhibition followed a classical hyperbolic shape, whereas cell respiration inhibition showed an S-shaped curve. Only when CI was inhibited by 35-40% (< 5 nM rotenone), cell respiration begun to decrease. Between 40 and 60% of CI inhibition (5-10 nM rotenone), cell respiration decreased linearly until 30% of the normal rate. Increasing concentrations of rotenone produced further but slower decrease in CI activity and cell respiration.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of complex I (NADH decylubiquinone reductase) inhibition on endogenous cell respiration. Cells were treated with different concentrations of rotenone for 4 h before measuring cell respiration in whole cells and CI activity in isolated mitochondria. Complete CI inhibition was achieved with 100 nM rotenone. The cell respiration was inhibited also in a dose-dependent manner but showed a different inhibition kinetics. HXC have an approximately 40% CI inhibition and an approximately 80% residual cell respiration (13).

Modeling a Genetically Determined 40% Complex I Inhibition by Using Human Xenomitochondrial Cybrids-- This cellular model of CI deficiency is caused by a limited number of amino acid changes in mtDNA-coded subunits (i.e. those amino acids that differ between humans and the three apes used in the creation of HXC (13).

Effect of Rotenone Treatment on the Steady-state Levels of mtDNA and Mitochondrial Respiratory Chain Complexes

To determine whether the inhibition of CI induced adaptative variations on the expression of the complex I and II subunits, immunoblotting was performed. Using mitochondria isolated from cells incubated with different concentrations of rotenone for 24 h, no significant changes in the ND1/SDH(Fp) ratio were observed (Fig. 2). A rotenone-induced CI deficiency did not produce an adaptive response in the form of an increased expression of the complex II (CII) in a period of 24 h.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of rotenone treatment on the steady-state levels mitochondrial respiratory chain complexes. Immunoblotting was performed using 40 µg of mitochondrial protein from 143B cells treated with different concentrations of rotenone for 24 h. Antibodies against SDH (Fp) and the subunit 1 of the NADH-dehydrogenase (ND1) were used. The ND1/SDH ratio of the densitometrical values of the correspondent bands did not show significant differences between untreated and rotenone-treated 143B cells.

Effect of CI Inhibition on Cell Growth

Respiratory competent 143B cells grew exponentially in medium containing glucose as carbon source, and they showed a substantial, although slightly reduced, growth rate in galactose-containing medium (Fig. 3A). The doubling time in glucose (DGlu) was approximately 17 h, and in galactose (DGal) it was 20 h (Fig. 3C). When 143B/206 rho ° cells were cultured in a medium in which glucose is substituted for galactose, these cells died and detached from the culture plate in less than 12 h (Fig. 3A), because galactose cannot be used efficiently for glycolysis. HXC, having a 40% CI deficiency, grew well in glucose-containing medium, with a DGlu of 23 h, but grew very poorly in galactose-containing medium with a DGal almost four times higher (Fig. 3). 143B cells were susceptible to the toxic properties of rotenone so that increasing concentrations (between 0 and 500 nM) produced progressively greater inhibition of the growth rate. Fig. 3B shows that 143B cells can grow in galactose medium in the presence of 5 nM rotenone (concentration inducing 54% of CI inhibition, Fig. 1) but not in the presence of 7.5 nM (72% of CI inhibition, Fig. 1). HXC cells grew in galactose medium if supplemented with less than 1 nM rotenone (concentration that produced approximately 19% of CI inhibition, Fig. 1). The rotenone-induced inhibition was additive to the genetically produced 40% deficiency in these cells. Fig. 3C compares growth parameters of the cell lines studied in the different culture conditions. The growth of the 143B/206 rho ° in glucose medium was affected by rotenone at concentrations >= 500 nM (the growth rate with 500 nM rotenone was 30% slower than untreated cells), and cells did not grow at a concentration of 600 nM. These data indicated that rotenone kills cells in a CI inhibition-independent way, when present at concentrations substantially higher than that producing complete CI inhibition in 143B cells.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of complex I inhibition on cell growth. A, human xenomitochondrial cybrid cell growth. Cells grew in Dulbecco's modified Eagle's medium lacking glucose supplemented with 5 mM glucose () or Dulbecco's modified Eagle's medium lacking glucose supplemented with 5 mM galactose (), both supplemented with 1 mM pyruvate and 10% dialyzed fetal calf serum. HXC lines (HC, human-common chimpanzee; HP, human-pigmy chimpanzee; HG, human-gorilla), which exhibited a 40% complex I deficiency, showed a reduced growth rate in both glucose and galactose medium compared with 143B cells. B, rotenone effects on cell growth. Concentrations from 0 to 500-nM rotenone produced progressively greater growth impairment of 143B in glucose medium. 143B/206 rho ° cells growth was affected only with high concentrations of the drug. In galactose medium, 5 nM rotenone (producing ~54% complex I inhibition) was enough to block 143B cell growth, whereas 1.5 nM rotenone (~20% of complex I inhibition) blocked cell growth in the 40% complex I defective HC (human-common chimpanzee xenomitochondrial cybrid) line. C, comparison of growth properties of rotenone-treated 143B cells and human-primate xenomitochondrial cybrids. The doubling time of different cell lines in medium containing glucose or galactose as the only carbon source, and the galactose/glucose medium ratio (number of cells in glucose medium at 72 h after plating divided by the number of cells in galactose medium at 72 h) were determined from the growth curves. Error bars represent the standard deviation of at least three independent measurements.

Effects of CI Inhibition on Oxidative Stress

Studies in HXC Lines-- We studied whether a 40% deficiency in CI activity resulted in greater reactive oxygen species (ROS) production in HXC lines. ROS production was estimated using H2DCF, a dye that is converted to a fluorescent product upon oxidation by hydrogen peroxide. Fig. 4A shows ROS production as a function of time. The slope of the regression lines was significantly higher in the HC (5.64 ± 0.25; p < 0.002), HP (5.07 ± 0.31; p < 0.016), and HG (5.09 ± 0.57; p < 0.050) xenomitochondrial cell lines compared with the set of values obtained for the 143B (4.22 ± 0.40) and SUB21 (4.67 ± 0.32) control cell lines. The electron transport in HXC may be inefficiently coupled to ATP synthesis, producing an increase in the rate of ROS formation. Lipid peroxidation is a deleterious consequence of oxidative stress. To determine whether the observed increase in the rate of ROS production in the HXC cell lines produced a higher lipid peroxidation of the membranes in these cells, the loss of cis-parinaric acid fluorescence was used to measure the chemical process of lipid peroxidation (26). In a whole cell assay, the time course of the fluorescence decrease showed no significant differences among cell lines (Fig. 4B). However, when using isolated mitochondria, an increase in the membrane lipid peroxidation was observed in HXC cells (Fig. 4C). The fluorescence value at the start of the reaction (t0) subtracted by the value measured after 30 min (t30), was 1.36-fold higher in HC (p = 0.015), 1.48-fold higher in HP (p = 0.044), and 1.51-fold higher in HG (p = 0.036), compared with the mean values obtained for the control human cell lines.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 4.   Oxidative stress studies in HXC cells. A, ROS production (monitored using H2DCFDA) as function of time. The slope of the regression lines was significantly higher for the HC, HP, and HG lines (p < 0.050) compared with two controls (143B and SUB21). B, lipid peroxidation (measured as loss of cis-parinaric acid fluorescence) using 50 µg of whole cells. No significant differences among cell lines were seen. C, lipid peroxidation of mitochondrial membranes by using 50 µg of isolated mitochondria. An increase in the membrane lipid peroxidation was observed in the HXC cells. The fluorescence value at the start of the reaction (t0) subtracted by the value measured after 30 min (t30) was ~1.5-fold increased in HXC (p < 0.02) with respect to the mean of the values obtained for the human cell lines. Error bars represent the standard deviation of the individual cell lines. HC, human-common chimpanzee; HP, human-pigmy chimpanzee; HG, human-gorilla; F.U., fluorescent units.

Studies in Rotenone-treated 143B Cells-- ROS production and mitochondrial membrane lipid peroxidation were enhanced by incubation of cells with rotenone (Fig. 5, A and B). Both parameters increased roughly linearly when concentrations of 0-100 nM rotenone were used (concentration range to produce CI inhibition) but did not increase significantly at higher concentrations. At the same concentration of rotenone, both parameters increased with longer treatment (between 4 and 72 h).


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of partial complex I inhibition on oxidative stress: studies in rotenone treated cells. A, studies of ROS production using the cell permeant probe H2DCFDA. B, Mitochondrial membrane lipid peroxidation studies monitored with the probe cis-parinaric acid. ROS production (estimated from hydrogen peroxide production) and mitochondrial membrane lipid peroxidation increased in rotenone-treated cells in a dose-dependent manner. In HXC cells, both parameters showed significant higher values than untreated 143B cells. C, studies of mitochondrial membrane potential (Delta psi m) at different concentrations of rotenone and duration of treatment. Delta psi m was estimated using JC-1, which forms aggregates in high Delta psi m conditions. The 590 nm (aggregate)/527 nm (monomer) ratio was considered an estimation of the Delta psi m. 143B cells treated with rotenone showed a decrease in the Delta psi m that did not reach the levels of 143B/206 rho ° cells. 143B/206 rho o showed a value of 30-32% of 143B, and 143B cells incubated for 45 min with 10 µM of the uncoupler carbonyl-cyanide m-chlorophenylhydrazone showed an estimated Delta psi m corresponding to 45-48% of the 143B value. HXC exhibited a Delta psi m of approximately 85% of untreated 143B.

Effect of CI Inhibition on the Mitochondrial Membrane Potential

A CI deficiency leads to a reduction in proton extrusion to the intermembrane space, partially depleting the cells from ATP. These factors, together with the associated increase in oxidative stress, could produce a significant drop of the mitochondrial membrane potential (Delta psi m). The dye JC-1 was used to monitor Delta psi m, estimated as the 590/527 nm emission ratio. Used as low Delta psi m controls, 143B/206 rho o value was 30-32% of 143B, and 143B cells incubated for 45 min with 10 µM of the uncoupler carbonyl-cyanide m-chlorophenylhydrazone showed an estimated Delta psi m corresponding to 45-48% of the 143B value (Fig. 5C). HXC lines exhibited a Delta psi m that was 83-87% of the 143B level. Rotenone-treated 143B cells showed a mild decrease in their Delta psi m (Fig. 5C). Low concentrations of rotenone (between 1 and 10 nM), produced a consistent hyperpolarization of the mitochondrial membrane (a reproducible 15-18% increase compared with the control level) when cells were incubated with the drug for 4 h. At those concentrations, the Delta psi m was maintained above 80% of the normal value. Only in cells that were incubated for 3 days with concentrations of rotenone between 100 and 600 nM did their Delta psi m decrease to 60-65% of the untreated 143B cell value. For each concentration of rotenone used, Delta psi m decreased slightly with the time of incubation.

Effect of CI Inhibition on Cell Death

143B and 143B/206 rho ° were treated with different concentrations of rotenone and harvested at 24, 48, and 72 h. In 143B cells, cell death was increased with all concentrations of rotenone up to 10-13 times the level of untreated cells after 3 days of incubation with 100 nM rotenone (Fig. 6A). Higher concentrations increased cell death exponentially. Rotenone did not significantly kill 143B/206 rho ° cells until present at concentrations higher than 100 nM. Using 600 nM rotenone, both cell lines died at indistinguishable rates (Fig. 6A). Experiments were carried out to test whether cell death in the presence of rotenone requires MPT. Fig. 6B shows the ability of 5 µM CyA and 50 µM ArA to prevent cell death from taking place in the presence of different concentrations of rotenone during 15 and 30 h. CyA inhibits the opening of the MPT pore (32), and phospholipase A2 inhibitors, such as ArA, enhance and prolong this effect (30, 31). Because CyA is not able to maintain mitochondrial function, it did not prevent rotenone-induced apoptosis after long periods of rotenone treatment. In cells treated with rotenone for 48 h, CyA essentially did not inhibit apoptosis (15-30% inhibition), even with changing the medium and adding fresh CyA every 8.5 h (data not shown). These data indicate that additional CyA-resistant mechanisms can have a role in the rotenone-induced apoptosis. ArA prolongs the effect of CyA for at least 16 h (31). We incubated the cells for 15 and 30 h with different concentrations of rotenone in the presence of CyA and ArA with a change of the medium in the latter at 15 h. When CyA and ArA were used in cells treated with < 500 nM rotenone, the cell death prevention was almost complete in the 15-h incubation experiments. However, cell death was prevented by 55-75% in the 30-h incubation experiments. In experiments using 600 nM of rotenone, cell death prevention dropped to under 50%. At these concentrations of rotenone, the mtDNA-less 143B/206 rho o cells also were killed, suggesting a second mechanism for rotenone toxicity.


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 6.   Effect of complex I inhibition on cell death. A, rotenone induced apoptosis in a dose-dependent manner at concentrations partially affecting CI activity in 143B cells and at higher concentrations in 143B and 143B/206 rho ° cells. B, CyA plus ArA prevention of rotenone-induced cell death. Incubation of cells with 5 µM CyA plus 50 µM ArA (see "Experimental Procedures") partially prevented killing of 143B cells after 15 or 30 h of chronic treatment with rotenone. The cell death prevention was higher at low concentrations of rotenone (see insets).

Exploring the Secondary Effects of Rotenone and Checking the Validity of the CI Inhibition Model

Rotenone seems to have at least two modes of action, because the mtDNA-less cell line was also killed by relatively high doses of the drug. To distinguish between these two effects and to define the effective range of rotenone concentrations that induce only or mostly a partial mitochondrial defect without major secondary effects, we studied the effect of rotenone in the microtubular cytoskeleton by immunocytochemical staining. 143B (data not shown) and 143B/206 rho o cells (Fig. 7) were treated with different concentrations of rotenone for 24 h and stained with a monoclonal antibody against tubulin. The nuclei were revealed by the specific dye Hoechst 3342. When the cells were incubated with 0-100 nM rotenone, a normal microtubular pattern and normal nuclear morphology were observed in all cells (Fig. 7). Concentrations of 500 nM rotenone produced a disorganization of the microtubular structure and condensation of the nucleus in approximately 5-10% of the cells (Fig. 7). By incubating cells with 1000 nM rotenone, more than 90% of the cells that still remained attached showed disruption of the microtubular network and condensation-fragmentation of the nucleus, which are typical apoptotic signs (Fig. 7).


View larger version (85K):
[in this window]
[in a new window]
 
Fig. 7.   Rotenone toxicity in mtDNA-less 143B/206 rho ° cells. Cell were incubated for 24 h with 100, 500, and 1000 nM rotenone and compared with untreated cells. To detect the microtubule network, cells were incubated with a monoclonal antibody against tubulin and a Texas Red-conjugated donkey anti-mouse IgG. Coverslips were incubated with Hoechst 3342 to reveal the nuclei. Cells growing in regular medium showed a typical pattern of microtubule and nucleus staining. After treatment with rotenone concentrations lower than 100 nM, no changes were observed. Using 500 nM rotenone, approximately 10% of cells showed a clear disruption of the microtubule network and condensation of the nucleus. By using 1 µM rotenone, more than 90% of the cells that remained attached presented disrupted microtubule network and micronucleation characteristic of apoptotic cells.

Correlations between CI Impairment and Physiological Consequences

After 72 h of rotenone treatment, the percentage of CI inhibition correlated positively, giving an exponential curve, with ROS production (R2 = 0.973), decay in Delta psi m (R2 = 0.985), mitochondrial membrane lipid peroxidation (R2 = 0.964), and apoptotic cell death (R2 = 0.924) (Fig. 8B). Because the effect of rotenone on CI inhibition and cell respiration was not exactly the same (Fig. 1), all the curves were modified accordingly, showing hyperbolic shapes, when cell respiration was plotted against all the parameters studied. In all cases, R2 was > 0.93 (Fig. 8A). Fig. 1 shows that incubation of 143B cells in medium supplemented with 1 nM rotenone exhibited a 19% of CI inhibition but maintained 98% of the cell respiration rate. Percentages of CI inhibition lower than 20% produced mild changes in all parameters, whereas any change in cell respiration produced significant increases in all of them (Fig. 8, A and B). A summary of our findings for four putative levels of CI deficiency is depicted in Fig. 8C.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 8.   Correlation between the percentage of complex I inhibition and the percentage of residual cell respiration with the physiological parameters studied. A, CI inhibition correlated exponentially with mitochondrial membrane potential decay (Delta psi m), ROS production, mitochondrial membrane lipid peroxidation, and cell death. B, percentage of cell respiration inhibition correlated with all the parameters giving a hyperbolic curve. The different shapes of the curves in A and B are explained because percentages of CI inhibition lower than 20% produced mild changes in all the parameters, whereas any change in cell respiration produced significant increases in all of them. C depicts a model whereby cells with a partial complex I deficiency (exemplified as 25, 50, 75, and 100% impairment) suffer different levels of physiological consequences. When mitochondrial electron transport is inhibited at CI, cells are depleted of ATP and ROS production is enhanced, damaging mitochondrial membranes, resulting in small membrane depolarization and permeability transition. These mitochondrial alterations are the starting point of a cascade of events promoting apoptosis. In response to mitochondrial impairment, a calcium efflux from mitochondria probably occurs, which could contribute to perpetuate a vicious cycle of MPT and ROS production, resulting in further complex I inhibition, disruption of calcium homeostasis, and cell death.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the last few years, many studies focused in the causal relationship between physiological or pathological decreases in mitochondrial polarization, ROS generation, the MPT, and subsequent apoptotic cell death (33-35). The main goal of the present work was to define quantitative correlations between partial mitochondrial CI inhibition and the physiological consequences at the cellular level by using a drug-induced model (rotenone dose-dependent CI inhibition in a human osteosarcoma-derived cell line) and a genetic model (40% CI inhibited HXC lines; Ref. 13).

Effect of CI Inhibition on Cell Respiration and Growth-- Exposure of 143B cells containing normal levels of mtDNA (rho + cells) to increasing concentrations of rotenone produced a progressive inhibition of CI activity and, subsequently, of cell respiration. We observed a hyperbolic titration curve of CI inhibition, whereas the cell respiration inhibition showed a sigmoidal curve. Our results suggest that there is an excess CI of activity relative to the maximum rate of electron flow through the respiratory chain. Consistent with the respiratory control theory (36), a reduction in CI activity up to 40% may be able to limit the flux rate of the electron transport chain only modestly. In the case of HXC, a 40% CI inhibition produced a 20% cell respiration reduction, which is in good agreement with the pharmacological model. Cultured cells, even the ones defective in oxidative phosphorylation, can grow at essentially normal rates in medium containing glucose, a sugar that can be well metabolized glycolytically. Using a medium in which galactose replaced glucose, cells were forced to derive much of their ATP from oxidative metabolism. The decrease in respiratory efficiency of the HXC and in the rotenone-treated cells reduced their rate of ATP production by oxidative phosphorylation to an extent sufficient to affect their growth capacity in galactose medium. A 65% CI inhibition, producing approximately a 35% inhibition in cell respiration, seems to be the threshold in our pharmacological model that allows cells to grow in conditions where the respiratory chain is essentially the only source of ATP. The rotenone-induced CI inhibition was additive to the genetically determined 40% CI deficiency in HXC cells (13). HXC cells could grow in galactose medium, although their doubling time was very high (~80 h). HXC cells were still able to grow in galactose medium for an additional ~20% CI inhibition (~5% cell respiration decline), showing that also in this model, the threshold seems to be ~60% CI inhibition (corresponding to ~35% cell respiration decay). This threshold may change with the cell type, depending on the control coefficient of their CI. Changes in the threshold can be the basis for understanding the cell type specificity of CI deficiencies in some neurodegenerative disorders such as Parkinson's disease. Our results suggest that if cells are maintained in glucose medium, a partial CI deficiency is more deleterious than a complete respiratory chain deficiency for some cellular functions. In glucose-containing medium, rho + cells experimented a rotenone dose-dependent (from 0 to 500 nM) reduction in their growth rate. rho ° cells did not experience any major change in their growth rate in glucose medium (<10%) at concentrations lower than 200 nM rotenone and decreased by only ~35% with 500 nM rotenone, a concentration that seems to be a threshold for killing these cells. It has been suggested that inhibition of respiratory chain activity by drugs such as rotenone directly interferes, as an acute insult, with the normal mitochondrial energy metabolism, triggering an apoptotic response. The generation of rho ° cell lines, on the other hand, undergoes a progressive mtDNA depletion by treatment with ethidium bromide during at least 30 days, a period of time that could allow the cells to adapt metabolically (23). Nevertheless, because cells with complete rotenone-induced CI inhibition still maintained a cell respiration rate of approximately 20% (because of the electron flow through the CII) and because of the gradual decline observed on the growth rate of rho + cells with partial CI inhibition in nonselective glucose medium, it is clear that factor(s) in addition to the oxidative impairment are implicated in the CI impairment.

Effect of CI Inhibition on Oxidative Damage-- In both genetic and pharmacological models, CI impairment was accompanied by an enhancement of ROS production and lipid peroxidation. Under aerobic conditions, the respiratory chain is a potent source of free radical (33, 37, 38). A CI impairment leads to enhanced formation of ROS, as has been shown in submitochondrial particles (16, 18) and in different cell systems (39, 40). In the case of HXC, defects in CI may predispose the respiratory chain to produce excess superoxide because of structural or stoichiometric alterations in the subunits. This alteration may lead to increased interaction of oxygen with an electron carrier, as it has been proposed for patients with genetically determined CI deficiency (39). In 143B cells treated with rotenone, ROS production increased in a dose-dependent manner. At 100% CI inhibition, the rate of ROS generation increased by a maximum of 20-25% in short term incubations (4 h). Similar results were reported on a human skin fibroblasts treated with 1 µM rotenone (39). This pattern is compatible with a scenario where ROS production may result directly from CI inhibition, being enhanced during the subsequent apoptotic process (see below). Activation of apoptosis has been associated with generation of ROS, and it has been shown that superoxide is produced by mitochondria isolated from apoptotic cells due to a switch from the normal four-electron reduction of O2 to a one-electron reduction when cytochrome c is released from mitochondria (41). It is still unclear whether the site of superoxide production in CI inhibited mitochondria is CI itself (16-19) or not (42). In any case, a partial inhibition of CI by rotenone should favor the transfer of electrons by CII and, as a consequence, an increase in the superoxide anion production. Electrons channeled via CII produce greater than four times more mitochondrial superoxide than electrons channeled via CI (43), and in studies in isolated cerebral mitochondria using succinate as substrate, ROS production was increased almost 9-fold (44). This problem will be of greater magnitude if cells try to compensate the CI impairment by overexpressing CII subunits. Although the question of whether CI inhibition up-regulates the mitochondrial CII activity was not directly addressed in this study, the unchanged ND1/SDH ratio observed in our experiments suggest that the compensatory mechanism in the form of CII overexpression, if any, cannot be observed in a period up to 24 h. The possible adaptive mechanisms in the form of modulation of enzymic activities of distal respiratory chain complexes, increase in mitochondrial content of the cell, or other effects in the mitochondrial biogenesis remain unknown and are currently under investigation.

It has been shown that CI inhibition induces increase in the MnSOD levels (39, 45). Because oxidative stress is considered an imbalance between oxidants being metabolized or scavenged by antioxidants, our work cannot discern whether the ROS generation was underestimated by the action of intramitochondrial scavenging activity. To evaluate the consequences of increased level of ROS under the circumstance of a partial CI impairment, we examined the degree of lipid peroxidation. Lipid peroxidation increased linearly until approximately 75% CI inhibition, remaining basically constant until total CI blockage. The increased membrane sensitivity to oxidants could be due to changes in membrane lipid composition (46) and may contribute to a decreased fluidity (47), affecting in turn parameters such as Delta psi m and cell death. Certainly, ROS have damaging effects on cellular components triggering defensive responses by the cells and even apoptosis (48, 49).

Effect of CI Inhibition on Delta psi m and Apoptosis-- Although the regulation of apoptosis is complex and not fully understood, it is known that mitochondria play an important role in the process. A reduction in Delta psi m is an early event in many cells undergoing apoptosis (50-53); isolated mitochondria induced to undergo MPT can induce nuclear apoptosis (53), CyA inhibits MPT pore opening, inhibiting apoptosis in some cases, and the subsequent loss of Delta psi m (31, 53, 54). It is interesting to consider whether or not a fall in Delta psi m is a signal for the CI impairment-associated cell death. According to this and previous studies (55), despite the failure to generate ATP oxidatively, rotenone only slightly depolarized mitochondria, maintaining more than 75% of control Delta psi m, even when CI was completely inhibited for long incubation periods (3 days). Glycolysis provides the cells with sufficient ATP, which can be used via the mitochondrial ADP/ATP translocator to create a Delta psi m across the mitochondrial inner membrane (56). Such a fall in Delta psi m may be insufficient to trigger apoptosis when cells grow in glucose medium, and additional biochemical insults (e.g. oxidative stress) may finally lead to cell death. It is interesting that by using concentrations of rotenone lower than 10 nM (~75% CI inhibition), mitochondria actually became hyperpolarized, especially under incubation times shorter than 48 h. Similar Delta psi m increases have been shown before in Jurkat cells early during the apoptotic response to different stimuli (57). As a result of a decreased electron transport, the rate of H+ ion delivery to the intermembrane space should be decreased. However, alterations in ionic homeostasis may produce an increase in that rate or a decrease in the removal of the H+ ions from the intermembrane space, inducing the observed hyperpolarization. When cells lose ion homeostasis, this scenario could be reversed, producing a fall in the Delta psi m. The rho ° cells used in this study maintained approximately 30% of the Delta psi m exhibited by the rho + cells (20% in previous studies using the dye R123; Ref. 56), enough to support a growth rate in glucose medium comparable with that from rho + cells. In the light of these results, HXC reduced growth rate in glucose medium cannot be explained by the 10-15% fall of their Delta psi m but probably because HXC cells suffer the consequences of a higher ROS production rate.

One of the early events in apoptosis seems to involve MPT triggered by a phosphorylation event or by the action of free radical (58). The MTP pore opening is mediated by collapse of Delta psi m, ROS, high levels of Ca2+, or low ATP. When these conditions are established, mitochondrial solutes leak out, and nuclear apoptosis is induced. CyA, an inhibitor of MPT, plus ArA, a phospholipase A2 inhibitor acting synergistically with CyA, prevented rotenone-induced cell death up to 80% at concentrations lower than 400 nM and up to 60% with higher concentrations. The ability of CyA to protect cells from death suggests that some of the physiological consequences of the CI impairment, such as a sudden reduction in ATP production (59), a decrease (even if small) in the Delta psi m, or an increase in the ROS production, can promote MPT. In agreement with our results, CI inhibitor-induced apoptosis in dopaminergic PC12 cells was prevented by CyA (40) and also by free radical scavengers (60), supporting the involvement of ROS in the pathway leading to apoptosis following CI inhibition.

Cellular Events Associated with CI Inhibition-- After chronic rotenone treatment (72 h) of 143B cells, the percentage of CI inhibition in these cell line correlates exponentially with all the physiological parameters studied. In Fig. 8C, the model of the mechanisms whereby cells incubated with rotenone suffer the physiological consequences of a mitochondrial dysfunction is depicted. Following the values for four putative levels of CI residual activity exemplified in the figure, we suggest that when electron transport is inhibited at the CI level, cells are depleted of ATP, and ROS production is enhanced, damaging mitochondrial membranes, resulting in slight membrane depolarization and MPT induction. These mitochondrial alterations are the starting point of a cascade of events promoting apoptosis. In response to respiratory chain impairment, a calcium efflux from mitochondria probably occurs, which could contribute to perpetuate a vicious cycle.

Our results show that the cytotoxicity of rotenone at high concentrations does not correlate to its inhibitory effect on CI because: (i) rho ° cells underwent apoptosis in the presence of high doses of rotenone; the levels of cell killing by concentrations of the drug higher than 600 nM were indistinguishable from those corresponding to rho + cells and (ii) rho + cells did not survive, even in high glucose medium, at concentrations of rotenone five times higher of that producing a total CI inhibition. It was important to address whether or not side effects of the drug would affect its use in creating pharmacological models of CI inhibition. Rotenone, at µM concentrations, is able to arrest mammalian cells in metaphase (61), not by inhibiting a specific energy-requiring step (62) but by binding directly to tubulin and preventing microtubule assembly (61, 63), similarly to colchicine or other "c-mitotic agents" (64). Our immunocytochemical studies demonstrated that by using rotenone concentrations that produce 0-100% of CI inhibition, the microtubule assembly was not affected, and no nuclear condensation was observed. Therefore, it is evident that the two modes of action of rotenone occur at nonoverlapping ranges of drug concentration, validating the rotenone-induced model of CI impairment.

Conclusions-- The goal of this study was to provide a comprehensive analyses of the cellular consequences of a partial complex I deficiency. Our chief conclusions were as follows: (i) We demonstrated a toxic effect of CI inhibition that is different from the one caused by a decrease in ATP production. This effect is likely to be mediated by increased free radical production, which triggers an apoptotic program. This cell death, however, could be prevented by blocking the mitochondrial permeability transition pore. (ii) Our studies validated rotenone inhibition as a good model for studying complex I, provided that the concentrations used do not exceed the ones sufficient to cause a complete inhibition of the enzyme, thus avoiding secondary toxicity. (iii) Finally, the quantitative correlation found among all the parameters studied provided a "guide" for the several physiological consequences of a partial CI inhibition at the cellular level and underscored the important deleterious effects of even a mild, chronic impairment in CI activity.

    ACKNOWLEDGEMENTS

We thank Dr. Ashok Verma and Dr. Runu Dey for critically reading the manuscript and all the members of the MitoClub (University of Miami) for constructive criticism. We are indebted to Dr. Michael P. King (Thomas Jefferson University, Philadelphia, PA) for the cell line 143B/206 rho °, Dr. R. A. Capaldi (Institute of Molecular Biology, University of Oregon, Eugene, OR) for SDH (Fp) monoclonal antibody, and Dr. A. Lombes (Groupe Hospitalier Pitié-Salpêtrière, INSERM U-153, Paris, France) for the human ND1 polyclonal antibody.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants GM55766 and EY10804.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Recipient of Grant 37289410 from the Spanish Ministerio de Educacion y Ciencia, FPI-Extranjero-1996.

parallel To whom reprint requests should be addressed: Dept. of Neurology, University of Miami, 1501 NW 9th Ave., Miami, FL 33136. E-mail: cmoraes{at}med.miami.edu.

    ABBREVIATIONS

The abbreviations used are: CI, complex I; CII, complex II; ArA, aristolochic acid; CyA, cyclosporin A; Fp, flavoprotein; HXC, human xenomitochondrial cybrids; LHON, Leber's hereditary optic neuropathy; mtDNA, mitochondrial DNA; MPT, mitochondrial permeability transition; SDH, succinate dehydrogenase; H2DCFDA, 2'-7' dichlorofluorescein diacetate; PBS, phosphate-buffered saline; JC-1, 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazole carbocyanide iodide; ROS, reactive oxygen species.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Walker, J. E. (1992) Q. Rev. Biophys. 25, 253-324[Medline] [Order article via Infotrieve]
  2. Chomyn, A., Cleeter, M. W., Ragan, C. I., Riley, M., Doolittle, R. F., and Attardi, G. (1986) Science 234, 614-618[Medline] [Order article via Infotrieve]
  3. Robinson, B. H., McKay, N., Goodyer, P., and Lancaster, G. (1985) Am. J. Hum. Genet. 37, 938-946[Medline] [Order article via Infotrieve]
  4. Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M., Elsas, L. J., III, and Nikoskelainen, E. K. (1988) Science 242, 1427-1430[Medline] [Order article via Infotrieve]
  5. Schapira, A. H., Cooper, J. M., Dexter, D., Jenner, P., Clark, J. B., and Marsden, C. D. (1989) Lancet 1, 1269[Medline] [Order article via Infotrieve]
  6. Robinson, B. H. (1993) Biochim. Biophys. Acta 1182, 231-244[Medline] [Order article via Infotrieve]
  7. Hofhaus, G., and Attardi, G. (1993) EMBO J. 12, 3043-3048[Abstract]
  8. Jun, A. S., Trounce, I. A., Brown, M. D., Shoffner, J. M., and Wallace, D. C. (1996) Mol. Cell. Biol. 16, 771-777[Abstract]
  9. Hofhaus, G., and Attardi, G. (1995) Mol. Cell. Biol. 15, 964-974[Abstract]
  10. Hofhaus, G., Johns, D. R., Hurko, O., Attardi, G., and Chomyn, A. (1996) J. Biol. Chem. 271, 13155-13161[Abstract/Free Full Text]
  11. Swerdlow, R. H., Parks, J. K., Miller, S. W., Tuttle, J. B., Trimmer, P. A., Sheehan, J. P., Bennett, J. P., Jr., Davis, R. E., and Parker, W. D., Jr. (1996) Ann. Neurol. 40, 663-671[Medline] [Order article via Infotrieve]
  12. Kenyon, L., and Moraes, C. T. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 9131-9135[Abstract/Free Full Text]
  13. Barrientos, A., Kenyon, L., and Moraes, C. T. (1998) J. Biol. Chem. 273, 14210-14217[Abstract/Free Full Text]
  14. Chance, B., and Hollunger, G. (1963) J. Biol. Chem. 238, 418-431[Free Full Text]
  15. Ramsay, R. R., and Singer, T. P. (1992) Biochem. Biophys. Res. Commun. 189, 47-52[Medline] [Order article via Infotrieve]
  16. Takeshige, K., and Minakami, S. (1979) Biochem. J. 180, 129-135[Medline] [Order article via Infotrieve]
  17. Takayanagi, R., Takeshige, K., and Minakami, S. (1980) Biochem. J. 192, 853-860[Medline] [Order article via Infotrieve]
  18. Turrens, J. F., and Boveris, A. (1980) Biochem. J. 191, 421-427[Medline] [Order article via Infotrieve]
  19. Hasegawa, E., Takeshige, K., Oishi, T., Murai, Y., and Minakami, S. (1990) Biochem. Biophys. Res. Commun. 170, 1049-1055[Medline] [Order article via Infotrieve]
  20. Langston, J. W., Ballard, P., Tetrud, J., and Irwin, I. (1983) Science 219, 979-980[Medline] [Order article via Infotrieve]
  21. Chiueh, C. C., Markey, S. P., Burns, R. S., Johannessen, J. N., Jacobowitz, D. M., and Kopin, I. J. (1984) Psychopharmacol. Bull. 20, 548-553[Medline] [Order article via Infotrieve]
  22. Cleeter, M. W., Cooper, J. M., and Schapira, A. H. (1992) J. Neurochem. 58, 786-789[Medline] [Order article via Infotrieve]
  23. King, M. P., and Attardi, G. (1989) Science 246, 500-503[Medline] [Order article via Infotrieve]
  24. Hao, H., and Moraes, C. T. (1996) J. Biol. Chem. 271, 2347-2352[Abstract/Free Full Text]
  25. Cathcart, R., Schwiers, E., and Ames, B. N. (1983) Anal. Biochem. 134, 111-116[Medline] [Order article via Infotrieve]
  26. Kuypers, F. A., van den Berg, J. J., Schalkwijk, C., Roelofsen, B., and Op den Kamp, J. A. (1987) Biochim. Biophys. Acta 921, 266-274[Medline] [Order article via Infotrieve]
  27. Hedley, D., and Chow, S. (1992) Cytometry 13, 686-692[Medline] [Order article via Infotrieve]
  28. Smiley, S. T., Reers, M., Mottola-Hartshorn, C., Lin, M., Chen, A., Smith, T. W., Steele, G. D., Jr., and Chen, L. B. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3671-3675[Abstract]
  29. Salvioli, S., Ardizzoni, A., Franceschi, C., and Cossarizza, A. (1997) FEBS Lett. 411, 77-82[CrossRef][Medline] [Order article via Infotrieve]
  30. Imberti, R., Nieminen, A. L., Herman, B., and Lemasters, J. J. (1992) Res. Commun. Chem. Pathol. Pharmacol. 78, 27-38[Medline] [Order article via Infotrieve]
  31. Pastorino, J. G., Chen, S. T., Tafani, M., Snyder, J. W., and Farber, J. L. (1998) J. Biol. Chem. 273, 7770-7775[Abstract/Free Full Text]
  32. Fournier, N., Ducet, G., and Crevat, A. (1987) J. Bioenerg. Biomembr. 19, 297-303[Medline] [Order article via Infotrieve]
  33. Boveris, A., and Chance, B. (1973) Biochem. J. 134, 707-716[Medline] [Order article via Infotrieve]
  34. Turrens, J. F., Alexandre, A., and Lehninger, A. L. (1985) Arch. Biochem. Biophys. 237, 408-414[Medline] [Order article via Infotrieve]
  35. Petit, P. X., Susin, S. A., Zamzami, N., Mignotte, B., and Kroemer, G. (1996) FEBS Lett. 396, 7-13[CrossRef][Medline] [Order article via Infotrieve]
  36. Mazat, J. P., Letellier, T., Bedes, F., Malgat, M., Korzeniewski, B., Jouaville, L. S., and Morkuniene, R. (1997) Mol. Cell. Biochem. 174, 143-148[CrossRef][Medline] [Order article via Infotrieve]
  37. Richter, C., and Frei, B. (1988) Free Radical Biol. Med. 4, 365-375[Medline] [Order article via Infotrieve]
  38. Beyer, R. E. (1992) Biochem. Cell Biol. 70, 390-403[Medline] [Order article via Infotrieve]
  39. Pitkanen, S., and Robinson, B. H. (1996) J. Clin. Invest. 98, 345-351[Abstract/Free Full Text]
  40. Seaton, T. A., Cooper, J. M., and Schapira, A. H. V. (1998) Brain Res. 809, 12-17[CrossRef][Medline] [Order article via Infotrieve]
  41. Cai, J., and Jones, D. P. (1998) J. Biol. Chem. 273, 11401-11404[Abstract/Free Full Text]
  42. Singer, T. P., and Ramsay, R. R. (1994) Biochim. Biophys. Acta 1187, 198-202[Medline] [Order article via Infotrieve]
  43. Pryor, W. A. (1982) Ann. N. Y. Acad. Sci. 393, 1-22
  44. Dykens, J. A. (1994) J. Neurochem. 63, 584-591[Medline] [Order article via Infotrieve]
  45. Luo, X., Pitkanen, S., Kassovska-Bratinova, S., Robinson, B. H., and Lehotay, D. C. (1997) J. Clin. Invest. 99, 2877-2882[Abstract/Free Full Text]
  46. Laganiere, S., and Yu, B. P. (1993) Gerontology 39, 7-18[Medline] [Order article via Infotrieve]
  47. Paradies, G., and Ruggiero, F. M. (1991) Arch. Biochem. Biophys. 284, 332-337[Medline] [Order article via Infotrieve]
  48. Goosens, V., Grooten, J., and De Vos, K. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8115-8119[Abstract]
  49. Hockenbery, D. M., Oltvai, Z. N., Yin, X. M., Milliman, C. L., and Korsmeyer, S. J. (1993) Cell 75, 241-251[Medline] [Order article via Infotrieve]
  50. Wolvetang, E. J., Johnson, K. L., Krauer, K., Ralph, S. J., and Linnane, A. W. (1994) FEBS Lett. 339, 40-44[CrossRef][Medline] [Order article via Infotrieve]
  51. Marchetti, P., Susin, S. A., Decaudin, D., Gamen, S., Castedo, M., Hirsch, T., Zamzami, N., Naval, J., Senik, A., and Kroemer, G. (1996) Cancer Res. 56, 2033-2038[Abstract]
  52. Zamzami, N., Marchetti, P., Castedo, M., Zanin, C., Vayssiere, J. L., Petit, P. X., and Kroemer, G. (1995) J. Exp. Med. 181, 1661-1672[Abstract]
  53. Zamzami, N., Marchetti, P., Castedo, M., Hirsch, T., Susin, S. A., Masse, B., and Kroemer, G. (1996) FEBS Lett. 384, 53-57[CrossRef][Medline] [Order article via Infotrieve]
  54. Petronilli, V., Cola, C., and Bernardi, P. (1993) J. Biol. Chem. 268, 1011-1016[Abstract/Free Full Text]
  55. Scott, I. D., Akerman, K. E., and Nicholls, D. G. (1980) Biochem. J. 192, 873-880[Medline] [Order article via Infotrieve]
  56. Buchet, K., and Godinot, C. (1998) J. Biol. Chem. 273, 22983-22989[Abstract/Free Full Text]
  57. Vander Heiden, M. G., Chandel, N. S., Williamson, E. K., Schumacker, P. T., and Thompson, C. B. (1997) Cell 91, 627-637[CrossRef][Medline] [Order article via Infotrieve]
  58. Hale, A. J., Smith, C. A., Sutherland, L. C., Stoneman, V. E., Longthorne, V., Culhane, A. C., and Williams, G. T. (1996) Eur. J. Biochem. 236, 1-26[Abstract]; Correction (1996) Eur. J. Biochem. 237, 884
  59. Simbula, G., Glascott, P. A., Jr., Akita, S., Hoek, J. B., and Farber, J. L. (1997) Am. J. Physiol. 273, C479-C488[Abstract/Free Full Text]
  60. Seaton, T. A., Cooper, J. M., and Schapira, A. H. (1997) Brain Res. 777, 110-118[CrossRef][Medline] [Order article via Infotrieve]
  61. Meisner, H. M., and Sorensen, L. (1966) Exp. Cell Res. 42, 291-295[Medline] [Order article via Infotrieve]
  62. Figueras, M. J., and Gosalvez, M. (1973) Eur. J. Cancer 9, 529-531[Medline] [Order article via Infotrieve]
  63. Brinkley, B. R., Barham, S. S., Barranco, S. C., and Fuller, G. M. (1974) Exp. Cell Res. 85, 41-46[Medline] [Order article via Infotrieve]
  64. Margulis, L. (1973) Int. Rev. Cytol. 34, 333-336[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.